San Luis Wealth Advisors LLC Takes Position in Kenvue Inc. (NYSE:KVUE)

San Luis Wealth Advisors LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 23,635 shares of the company's stock, valued at approximately $567,000.

Several other hedge funds have also bought and sold shares of the stock. LaFleur & Godfrey LLC increased its stake in shares of Kenvue by 29.8% in the fourth quarter. LaFleur & Godfrey LLC now owns 81,300 shares of the company's stock worth $1,736,000 after buying an additional 18,650 shares during the period. Savant Capital LLC increased its stake in shares of Kenvue by 5.2% in the fourth quarter. Savant Capital LLC now owns 16,241 shares of the company's stock worth $347,000 after buying an additional 798 shares during the period. Vontobel Holding Ltd. increased its stake in shares of Kenvue by 38.7% in the fourth quarter. Vontobel Holding Ltd. now owns 31,335 shares of the company's stock worth $669,000 after buying an additional 8,741 shares during the period. Principal Securities Inc. increased its stake in shares of Kenvue by 1,103.6% in the fourth quarter. Principal Securities Inc. now owns 44,378 shares of the company's stock worth $947,000 after buying an additional 40,691 shares during the period. Finally, Allworth Financial LP increased its stake in shares of Kenvue by 90.2% in the fourth quarter. Allworth Financial LP now owns 38,082 shares of the company's stock worth $790,000 after buying an additional 18,059 shares during the period. 97.64% of the stock is currently owned by institutional investors.

Kenvue Trading Up 0.9%

Shares of KVUE opened at $21.65 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $25.17. The company has a 50 day simple moving average of $23.03 and a two-hundred day simple moving average of $22.48. The firm has a market cap of $41.53 billion, a P/E ratio of 40.84, a price-to-earnings-growth ratio of 2.62 and a beta of 0.98.

Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same period last year, the firm posted $0.28 EPS. The company's revenue was down 3.9% on a year-over-year basis. On average, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.79%. Kenvue's dividend payout ratio is currently 149.09%.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of research analyst reports. Barclays boosted their price objective on shares of Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Citigroup reaffirmed a "neutral" rating on shares of Kenvue in a research report on Friday. Evercore ISI started coverage on shares of Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price target on the stock. Piper Sandler upped their price target on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Finally, Redburn Atlantic started coverage on shares of Kenvue in a research note on Thursday, April 10th. They issued a "neutral" rating and a $23.50 price target on the stock. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.